Related Experiment Video

Updated: Apr 11, 2026

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

6.2K

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

John C Hunter1, Anuj Manandhar1, Martin A Carrasco1

  • 1Departments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.

Molecular Cancer Research : MCR
|June 4, 2015
PubMed
Abstract

Insights

Different KRAS mutations exhibit unique biochemical behaviors, influencing cancer signaling. Understanding these KRAS isoforms and their interactions with RAF kinase is key for developing targeted cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • KRAS mutations are prevalent in cancer, yet specific mutations show varied clinical responses.
  • Understanding the biochemical differences between KRAS isoforms is crucial for targeted therapy development.

Purpose of the Study:

  • To biochemically characterize common KRAS mutants.
  • To investigate substrate binding, GTPase activities, and RAF kinase interactions.
  • To explore therapeutic strategies for specific KRAS isoforms.

Main Methods:

  • Biochemical characterization of KRAS mutants.
  • Analysis of substrate binding kinetics and GTPase activities.
  • X-ray crystallography for structural insights.
  • Assessment of interactions with RAF kinase.

Main Results:

  • KRAS G13D exhibits rapid nucleotide exchange kinetics compared to other mutants.
  • X-ray crystallography revealed structural insights into GDP-bound KRAS G12V, G12R, and Q61L.
  • Biochemical properties correlate with KRAS-driven tumor signaling through RAF.

Conclusions:

  • Biochemical profiling of KRAS mutants provides insights into cancer signaling pathways.
  • Subclassification of KRAS-driven cancers facilitates rational therapy selection.
  • Targeting specific KRAS isoforms or RAS effectors can improve cancer treatment outcomes.

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.4K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
12.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K